From GlobeNewswire: 2025-06-06 09:20:00

The Anesthesia Drugs Market was valued at USD 5.9 billion in 2023, projected to reach USD 8.6 billion by 2032, with a 4.2% CAGR. Factors driving growth include global surgical procedure increases, demand due to chronic diseases, aging populations, and expanding healthcare services. Major players include Baxter, Pfizer, Abbott Laboratories, and more.

In the U.S., the Anesthesia Drugs market was valued at USD 1.57 billion in 2023, expected to reach USD 2.21 billion by 2032, with a 3.74% CAGR. The U.S. holds the largest share in North America due to high surgical procedure numbers and strong healthcare infrastructure.

The propofol segment dominates the market with a 25.7% share, known for rapid onset and recovery times. The IV segment leads with a 64.7% share, favored for precise dosage control. Knee and hip replacement procedures drive anesthesia demand, with hospitals accounting for 68.8% of the market share.

North America currently leads the Anesthesia Drugs Market, with Asia-Pacific expected to register the fastest growth, thanks to rising healthcare expenditure and surgical procedures. China and India are enhancing hospital availability and access, contributing to market growth.



Read more at GlobeNewswire: Anesthesia Drugs Market Set to Reach USD 8.6 Billion by